These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38604404)

  • 41. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
    Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
    Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
    Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective Evaluation of Exacerbations Associated with Suboptimal Peak Inspiratory Flow Among Stable Outpatients with COPD.
    Mahler DA; Niu X; Deering KL; Dembek C
    Int J Chron Obstruct Pulmon Dis; 2022; 17():559-568. PubMed ID: 35313719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
    Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
    COPD; 2016; 13(2):167-75. PubMed ID: 26516724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peak-Inspiratory-Flow-Rate Guided Inhalation Therapy Reduce Severe Exacerbation of COPD.
    Chen SY; Huang CK; Peng HC; Tsai HC; Huang SY; Yu CJ; Chien JY
    Front Pharmacol; 2021; 12():704316. PubMed ID: 34267665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease.
    Mahler DA
    Ann Am Thorac Soc; 2017 Jul; 14(7):1103-1107. PubMed ID: 28481631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The inhalation characteristics of patients when they use different dry powder inhalers.
    Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
    J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
    Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow.
    Huber B; Keller C; Jenkins M; Raza A; Aurivillius M
    Ther Adv Respir Dis; 2022; 16():17534666221107312. PubMed ID: 35815354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
    Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Characterization of Nursing Facility Residents With Chronic Obstructive Pulmonary Disease.
    Davidson HE; Radlowski P; Han L; Shireman TI; Dembek C; Niu X; Gravenstein S
    Sr Care Pharm; 2021 May; 36(5):248-257. PubMed ID: 33879286
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Misuse of inhalers among COPD patients in a community hospital in Taiwan.
    Liang CY; Chen YJ; Sheu SM; Tsai CF; Chen W
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1309-1316. PubMed ID: 29719386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ
    Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Study of Inhaler Device Handling Technique and Risk Factors for Critical Inhaler Errors in Korean COPD Patients.
    Jang JG; Chung JH; Shin KC; Jin HJ; Lee KH; Ahn JH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1051-1059. PubMed ID: 33907392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers.
    Broeders ME; Molema J; Vermue NA; Folgering HT
    Eur Respir J; 2001 Nov; 18(5):780-3. PubMed ID: 11757627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey.
    Öztürk C; Kaya A; Bilgin C; Yücesoy L; İkidağ B; Demirel M; Başlılar Ş; Şaylan B; Senol T; Ağanoğlu S; Can G; Doğrul MI; Çam M; Erdoğan N; Batum Ö; Turan MO; Demir C; Torun Ş; Cirit M; Turan M; Keleşoğlu A; Yaşar S; Uzunay Ö; Melek K; Altıparmak O
    Tuberk Toraks; 2012; 60(4):301-13. PubMed ID: 23289459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Measurement of inspiratory flow for the selection of the inhalation treatment device for asthma and COPD].
    Plavec D; Gluncić TJ; Gudelj I; Mise K
    Lijec Vjesn; 2012; 134(3-4):84-9. PubMed ID: 22768682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.
    Loh CH; Peters SP; Lovings TM; Ohar JA
    Ann Am Thorac Soc; 2017 Aug; 14(8):1305-1311. PubMed ID: 28406710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
    Virchow JC; Weuthen T; Harmer QJ; Jones S
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.